Circulating tumour DNA (ctDNA) has emerged as a promising biomarker enabling the detection of minimal residual disease (MRD) in patients with locally advanced colon cancer. The phase II/III DYNAMIC-III trial, with results recently reported, is a landmark effort to evaluate ctDNA-guided adjuvant treatment in this setting. Here, I discuss how, despite not yet changing clinical practice, these results provide essential insights to guide the next generation of ctDNA-driven trials.
